EP4387734A1 - Procédé destiné à empêcher l'entrée et la réplication de virus enveloppés - Google Patents

Procédé destiné à empêcher l'entrée et la réplication de virus enveloppés

Info

Publication number
EP4387734A1
EP4387734A1 EP22861909.4A EP22861909A EP4387734A1 EP 4387734 A1 EP4387734 A1 EP 4387734A1 EP 22861909 A EP22861909 A EP 22861909A EP 4387734 A1 EP4387734 A1 EP 4387734A1
Authority
EP
European Patent Office
Prior art keywords
zinc
quercetin
administration
cyclodextrin
entry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22861909.4A
Other languages
German (de)
English (en)
Inventor
Bhanu Pratap Jena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viron Inc
Original Assignee
Viron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/472,604 external-priority patent/US20230082992A1/en
Application filed by Viron Inc filed Critical Viron Inc
Priority to EP24167332.6A priority Critical patent/EP4393497A3/fr
Publication of EP4387734A1 publication Critical patent/EP4387734A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Definitions

  • Certain embodiments of the present invention relate to the prevention of enveloped viral entry into cells. Still other embodiments prevent the replication of enveloped viruses should cell entry occur.
  • the cell plasma membrane of skin and lung epithelia is the first line of defense and when breached serves as the portal for viral entry into hosts.
  • It is established that viral binding to a host cell membrane is subject to the presence of docking sites or receptors which, in turn, are regulated by membrane lipid composition and distribution. An example is the establishment of domains called rafts.
  • M-PCD methyl-beta-cyclodextrin
  • CDs cyclodextrins
  • lipid rafts facilitate the cellular entry or infection of HIV, its assembly, and its release from infected cells.
  • Lipid rafts are domains within the lipid bilayer, usually localized to the external leaf of the bilayer, present in many cell types, and implicated in a variety of sorting and signaling processes. These lipid rafts tend to be enriched in cholesterol and sphingolipids. Additional studies further report that plasma membrane cholesterol is also required for a wide range of both bacterial and yeast infections. Furthermore, a high-cholesterol diet impairs pulmonary host defense against gramnegative bacteria and Mycobacterium tuberculosis.
  • Cyclodextrins are a family of cyclic oligosaccharides constituted of a macrocyclic ring of glucose subunits joined by a- 1,4 glycosidic bonds. CDs are used for improving the watersolubility and bioavailability of a wide range of drugs.
  • the U.S. Food and Drug Administration (FDA) has approved the use of cyclodextrins since 2001. Cyclodextrins were first employed in the food industry in the 1970s, and since then they have been used as food additives for carrying food- related lipophiles such as vitamins, aromas and colorants.
  • PCD has also been used as a cholesterol-reducing agent in food of animal origin such as milk and egg.
  • the first pharmaceutical patent related to CDs and pharmaceutical applicability as complexing agents is dated 1953.
  • CDs are employed in pharmaceutical products primarily to increase water solubility of poorly soluble drug formulations and to enhance drug bioavailability.
  • Pharmaceutical products containing CDs comprise nasal spray, oral solutions, solid dosage forms, ocular and dermal formulations, suppositories, and parenteral solutions.
  • more than 40 pharmaceutical products containing CDs are available on the market worldwide, and many of them utilize PCD and its derivatives having higher water solubility, such as HPpCD, MpCD, and SBEpCD.
  • CDs are used for example in tablets, aqueous parenteral solutions, nasal sprays, and eye drop solutions.
  • Examples of the use of cyclodextrins in medicines on the European market are: P-CD in cetirizine tablets and cisapride suppositories; y- CD in minoxidil solution.
  • Examples of the use of P-cyclodextrin derivatives can include: SBE-P- CD in the intravenous antimycotic voriconazole; HP-P-CD in the antifungal itraconazole intravenous and oral solutions; and, RM-P-CD in a nasal spray for hormone replacement therapy by 17P-estradiol.
  • CDs may be at concentrations between one (1) and ten (10) percent.
  • a particular cyclodextrin may be hydroxypropyl-beta-cyclodextrin (HPpCD) in an aqueous phosphate-buffered saline solution. Such solution may be at a pH of 5-7.5. Further embodiments may contain 0.01% benzylkonium chloride. In additional embodiments the cyclodextrin may be at least one selected from the group of: aCD, PCD, yCD, MpCD, and SBEpCD.
  • HPpCD hydroxypropyl-beta-cyclodextrin
  • 1-20 pg mL' 1 quercetin is administered as part of the mixture.
  • solubilized zinc is administered as part of the formulation.
  • the solubilized zinc may administered at a concentration of 2-10 pg mL' 1 .
  • the solution is provided at pH 2.5 and the concentration of benzylkonium is at 0.01%.
  • the solution is provided at pH 7.5 with a benzylkonium concentration of 0.01%.
  • the solution may be applied topically to the skin either as a spray or as a wipe.
  • Still other embodiments include application via a cellulose mask.
  • CDs such as aCD, PCD, and yCD are hydrophilic in aqueous solutions, however they tend to self-assemble and form complexes.
  • soluble PCD derivatives such as 2-hydroxypropyl-pCD (HPpCD) and sulfobutylether PCD sodium salt (SBEpCD), are preferred for use in aqueous pharmaceutical formulations.
  • Inorganic acids such as phosphoric and citric acid induce CD solubilization.
  • Zinc is an essential trace element supporting growth, development and immune health. Zinc is also known to protect against viruses by inhibiting RNA binding, RNA synthesis, viral polyprotein cleavage, viral replication, and viral protease enzyme inactivation. However, in order to protect against viral infection, zinc needs to enter a host cell. Quercetin, a naturally occurring plant-based over-the-counter zinc ionophore, enables the cellular entry of zinc into host cells. Furthermore, quercetin has shown therapeutic effects against influenza virus.
  • Formulations of the present invention utilize CDs at FDA approved concentrations (e.g., between one (1) and ten (10) percent weight per volume; 1-10% w V 1 ) in combination with quercetin and zinc in pH buffered solutions to retain both high solubility and sterility.
  • Modes of administration can include aerosol spray, nebulization; and, topical application on the surface of a body using a water-based solution adsorbed to paper, cellulose or fabric.
  • the topical application on body surfaces includes specific application to the face and neck, to mitigate envelope virus (e.g., COVID-19 virus (SARS-CoV-2), influenza, and HIV), bacterial and fungal infections.
  • envelope virus e.g., COVID-19 virus (SARS-CoV-2), influenza, and HIV
  • bacterial and fungal infections e.g., COVID-19 virus (SARS-CoV-2), influenza, and HIV
  • the invention provides the use of a formulation containing cyclodextrins, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses, such as COVID-19 virus (SARS-CoV-2), influenza, and HIV.
  • This formulation may be adapted for both topical use or respiratory system introduction to a subject by dispersal utilizing known methods such as measured nasal sprays, nebulizers, inhalers, wet wipes and medicated masks.
  • the formulation is introduced in the form of an aqueous phosphate buffered saline pH 7.5 solution, containing 0.01% benzylkonium chloride as preservative and different concentrations of the active ingredients: 1-5% cyclodextrin; the flavonoid quercetin at a concentration of 8 pg mL' 1 ; and, 1 mg mL' 1 zinc chloride.
  • the aqueous solution may be in some embodiments citrate buffered at pH 2.5.
  • the low pH serves as a preservative and a solvent for CDs.
  • cyclodextrin molecules prevent the entry of enveloped viruses into host cells by extracting and sequestering cholesterol molecules at the virus coat/envelope and at the host cell plasma membrane.
  • the quercetin in the formulation enables cellular entry of zinc; which, in turn, inhibits viral replication by altering polymerase activity in the host cell.
  • CDs will allow the extraction of cholesterol molecules from enveloped virus membranes and the host cell membrane, altering their respective lipid and protein composition and distribution, preventing virus entry into host cells.
  • the quercetin acting as a zinc ionophore, enables the cellular entry of zinc.
  • the zinc functions to protect host cells against the envelope virus by inhibiting RNA binding, RNA synthesis, viral polyprotein cleavage, viral replication, and viral protease enzyme inactivation, among others.
  • RNA binding RNA binding
  • RNA synthesis viral polyprotein cleavage
  • viral replication viral protease enzyme inactivation
  • both viral entry and replication are prevented thereby decreasing the viral particle load present in or on a subject. Therefore, embodiments of the invention may be used prophylactically to prevent infection, or, may be used therapeutically to alleviate the associated effects of viral exposure and/or infection.
  • Certain embodiments provide an aerosol spray and nebulization of the combined cyclodextrin, quercetin and zinc as a aqueous phosphate buffered saline pH 7.5 solution containing 0.01% benzylkonium chloride as preservative.
  • the embodiment is administered as a prophylactic to protect the airways, including the lungs, from infections with enveloped viruses.
  • different particle sizes may be combined (e.g., a nebulizer treatment supplemented with an inhaler).
  • topical application of the combined cyclodextrin, quercetin and zinc in aqueous phosphate buffered saline pH 7.5 solution containing 0.01% benzylkonium chloride as preservative will be used to protect body surface (skin) from infections with enveloped viruses
  • the formulation is adapted for use and introduction to a subject by dispersal, utilizing any known method of measured nasal sprays or inhalers.
  • the formulation is introduced in form of an aqueous phosphate buffered saline pH 5-7.5 solution, containing 0.01% benzylkonium chloride as preservative and different concentrations of the active ingredients: 1- 5% cyclodextrin; and the flavonoid quercetin, a naturally occurring zinc ionophore at a concentration of 8-24 pg ml’ 1 .
  • pH 2.5 citrate buffered aqueous may also be used, where the low pH serves as a preservative and a solvent for cyclodextrin.
  • cyclodextrin alone is followed by quercetin and zinc administration (alone or combined), in a water based soluble formulation that prevents both viral entry and replication in host cells, such as the nasal epithelial cells and that of the lung epithelia.
  • the formulation may be administered as an aerosol spray or nebulization.
  • a particular embodiment contemplates an aqueous phosphate buffered saline pH 7.5 solution containing 0.01% benzylkonium chloride as preservative, will be used to protect the airways including lungs from all coat virus infections.
  • the above formulations may be topically applied; for example, via oils, creams, emulsions and the like the formulations of which are known to those skilled in the art.
  • Additional embodiments include application of the above solutions to both sides of cellulose masks. In such medicated masks, any airborne droplets containing the virus will be neutralized on contact with the medicated mask.
  • the effective dose and method of administration of a particular embodiment of the instant invention may vary based on the individual patient and stage of any present diseases (e.g., influenza, covid, HIV, other co-morbidities), as well as other factors known to those of skill in the art. Dosages of the above described embodiments result in a decrease in viral particle load through the above described mechanisms of action. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
  • ED50 the dose therapeutically effective in 50% of the population
  • LD50 the dose lethal to 50% of the population
  • compositions that exhibit large therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • the exact dosage may be chosen by an individual physician in view of a patient to be treated. Dosage and administration are adjusted to provide sufficient levels of embodiments of the instant invention to maintain the desired effect (e.g., elimination or reduction of enveloped virus particles or activity in a host). Additional factors that may be taken into account include the severity of any disease state, age, weight, and gender of the patient; diet, time and frequency of the administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy.
  • Short acting pharmaceutical compositions are administered daily whereas long acting pharmaceutical compositions are administered every 2, 3 to 4 days, every week, or once every two weeks or more.
  • the pharmaceutical compositions of the instant invention may be administered once, twice, three, four, five, six, seven, eight, nine, ten or more times per day.
  • Normal dosage amounts for active ingredients may vary from approximately 1 to 100,000 micrograms, up to a total dose of about 10 grams, depending upon the route of administration. Desirable dosages include 250 pg, 500 pg, 1 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 1 g, 1.1 g, 1.2 g, 1.3 g, 1.4 g, 1.5 g, 1.6 g, 1.7 g, 1.8 g, 1.9 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, and 10 g.
  • the dosage of the active ingredients described herein are those that provides sufficient quantity to attain a desirable effect, including those above-described effects. Accordingly, the dose of the active ingredients preferably produces a tissue or blood concentration of both about 1 to 800 pM. Preferable doses produces a tissue or blood concentration of greater than about 10 pM to about 500 pM.
  • Preferable doses are, for example, the amount of active ingredients required to achieve a tissue or blood concentration or both of 10 pM, 15 pM, 20 pM, 25 pM, 30 pM, 35 pM, 40 pM, 45 pM, 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 pM, 100 pM, 110 pM, 120 pM, 130 pM, 140 pM, 150 pM, 160 pM, 170 pM, 180 pM, 190 pM, 200 pM, 220 pM, 240 pM, 250 pM, 260 pM, 280 pM, 300 pM, 320 pM, 340 pM, 360 pM, 380 pM, 400 pM, 420 pM, 440 pM, 460 pM,
  • the pharmacologically active compounds of this invention can be processed in accordance with conventional methods of galenic pharmacy to produce medicinal agents for administration to patients (e.g., mammals including humans).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation d'une formulation contenant de la cyclodextrine, de la quercétine et du zinc à des concentrations appropriées pour atténuer les infections par des virus enveloppés. Tandis que les différentes formes de cyclodextrine empêchent l'entrée de virus revêtus dans des cellules hôtes par extraction et séquestration de molécules de cholestérol au niveau de l'enveloppe du virus et au niveau de la membrane plasmique de la cellule hôte, la quercétine ionophore permet l'entrée cellulaire de zinc, ce qui permet d'inhiber la réplication virale par modification de l'activité polymérase dans la cellule hôte.
EP22861909.4A 2021-08-22 2022-08-18 Procédé destiné à empêcher l'entrée et la réplication de virus enveloppés Pending EP4387734A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24167332.6A EP4393497A3 (fr) 2021-08-22 2022-08-18 Procédé pour empêcher l'entrée et la réplication de virus enveloppés

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163235772P 2021-08-22 2021-08-22
US17/472,604 US20230082992A1 (en) 2021-09-11 2021-09-11 Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
US202163294067P 2021-12-27 2021-12-27
US202263308782P 2022-02-10 2022-02-10
US202263396040P 2022-08-08 2022-08-08
PCT/US2022/040749 WO2023027939A1 (fr) 2021-08-22 2022-08-18 Procédé destiné à empêcher l'entrée et la réplication de virus enveloppés

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP24167332.6A Division-Into EP4393497A3 (fr) 2021-08-22 2022-08-18 Procédé pour empêcher l'entrée et la réplication de virus enveloppés
EP24167332.6A Division EP4393497A3 (fr) 2021-08-22 2022-08-18 Procédé pour empêcher l'entrée et la réplication de virus enveloppés

Publications (1)

Publication Number Publication Date
EP4387734A1 true EP4387734A1 (fr) 2024-06-26

Family

ID=85323261

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22861909.4A Pending EP4387734A1 (fr) 2021-08-22 2022-08-18 Procédé destiné à empêcher l'entrée et la réplication de virus enveloppés
EP24167332.6A Pending EP4393497A3 (fr) 2021-08-22 2022-08-18 Procédé pour empêcher l'entrée et la réplication de virus enveloppés

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP24167332.6A Pending EP4393497A3 (fr) 2021-08-22 2022-08-18 Procédé pour empêcher l'entrée et la réplication de virus enveloppés

Country Status (2)

Country Link
EP (2) EP4387734A1 (fr)
WO (1) WO2023027939A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0775536A (ja) * 1993-06-17 1995-03-20 Oomiya Yakugyo Kk ケルセチン配糖体を含有する清涼飲料水
EP1868628B1 (fr) * 2005-04-08 2014-06-11 Chimerix, Inc. Composes, compositions et methodes de traitement des infections a poxvirus
WO2010042633A2 (fr) * 2008-10-08 2010-04-15 The General Hospital Corporation Complexes de naringénine et méthodes d'utilisation associés
US11648261B2 (en) * 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
KR20160079473A (ko) * 2014-12-26 2016-07-06 (주)피치켐 녹차 추출물을 유효성분으로 포함하여 항바이러스 활성을 가지는 세정 또는 소독용 조성물 제조방법
WO2021168173A1 (fr) * 2020-02-20 2021-08-26 Synkine Therapeutics, Inc. Méthodes et compositions pour le traitement d'infections respiratoires virales
US20220409653A1 (en) * 2020-05-02 2022-12-29 Viron, Inc. Method for preventing entry and replication of enveloped viruses
JP2023550838A (ja) * 2020-11-25 2023-12-05 フォックスバイオ リミテッド ウィルス感染の低減

Also Published As

Publication number Publication date
WO2023027939A1 (fr) 2023-03-02
EP4393497A2 (fr) 2024-07-03
EP4393497A3 (fr) 2024-08-21

Similar Documents

Publication Publication Date Title
AU2010203026B2 (en) Nasal pharmaceutical formulations and methods of using the same
WO2019157099A1 (fr) Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie
US20060039871A1 (en) Nasal pharmaceutical formulations and methods of using the same
EP2594283B1 (fr) Préparation aérosol à base d'aprotinine pour traiter les infections respiratoires virales
RU2701514C2 (ru) Антивирусная фармацевтическая композиция
US20220409653A1 (en) Method for preventing entry and replication of enveloped viruses
US20230355517A1 (en) Use of active substances with antiviral, anti malarial, and/or mucolytic properties in the treatment of viral lung diseases including covid-19 by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
EP4387734A1 (fr) Procédé destiné à empêcher l'entrée et la réplication de virus enveloppés
WO2024035526A1 (fr) Utilisation combinée de nanocorps, de cyclodextrine et de quercétine pour la protection contre des virus enveloppés
US20230357329A1 (en) Combined use of nanobody, cyclodextrin and quercetin for protection from enveloped viruses
US20230414650A1 (en) Inhalation and topical use of a formulation containing cyclodextrin, quercetin and zinc, to mitigate infection by enveloped viruses, such as hiv and sars-cov-2
EP3678649B1 (fr) Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie
AU2020298557A1 (en) Compositions and methods useful for Ebola virus infection
US20240165191A1 (en) Compositions and methods for reducing the transmissivity of illnesses using an oral delivery system
TR2023001692T2 (tr) Anti̇vi̇ral, anti̇malaryal ve/veya mukoli̇ti̇k özelli̇kli̇ etki̇n maddeleri̇n yumuşak buğu i̇nhaler veya ti̇treşi̇mli̇ elek teknoloji̇si̇ nebuli̇zer vasitasiyla i̇nhale yolla covid-19 dahi̇l vi̇ral akci̇ğer hastaliklarinin tedavi̇si̇nde kullanimi
US20230082992A1 (en) Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
CN116437903A (zh) 肝素组合物在通过吸入途径通过软雾吸入器或振动网状技术雾化器治疗病毒性肺病、急性和/或慢性肺病中的用途
TW201717984A (zh) 用於治療及預防病毒感染之組合物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240314

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR